MX9602689A - Usos terapeuticos humanos de los productos de proteina bpi. - Google Patents
Usos terapeuticos humanos de los productos de proteina bpi.Info
- Publication number
- MX9602689A MX9602689A MX9602689A MX9602689A MX9602689A MX 9602689 A MX9602689 A MX 9602689A MX 9602689 A MX9602689 A MX 9602689A MX 9602689 A MX9602689 A MX 9602689A MX 9602689 A MX9602689 A MX 9602689A
- Authority
- MX
- Mexico
- Prior art keywords
- protein products
- therapeutic uses
- human therapeutic
- bpi protein
- observed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se dan a conocer métodos para el tratamiento de seres humanos expuestos a endotoxina bacteriana en circulacion mediante la administracion de productos de proteína (BPI) que aumentan el efecto bactericida/permeabilidad. El alivio serologica y hematologicamente verificable de aumentos mediados de endotoxina en citocinas, fibrinolisis y factores de coagulacion en circulacion y los cambios en cuentas de linfocitos se observan durante este tratamiento. Se observa también el alivio de disminuciones mediadas de endotoxina en el índice de resistencia vascular sistemática (SVRI) y los aumentos concomitantes en el índice cardíaco (CI).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18822194A | 1994-01-24 | 1994-01-24 | |
US08/291,112 US5643875A (en) | 1994-01-24 | 1994-08-16 | Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products |
PCT/US1995/001151 WO1995019784A1 (en) | 1994-01-24 | 1995-01-24 | Human therapeutic uses of bpi protein products |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9602689A true MX9602689A (es) | 1997-05-31 |
Family
ID=26883856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9602689A MX9602689A (es) | 1994-01-24 | 1995-01-24 | Usos terapeuticos humanos de los productos de proteina bpi. |
Country Status (9)
Country | Link |
---|---|
US (5) | US5643875A (es) |
EP (2) | EP1161952A3 (es) |
JP (2) | JPH09508130A (es) |
CN (1) | CN1145033A (es) |
AU (1) | AU703728B2 (es) |
CA (1) | CA2181816A1 (es) |
HK (1) | HK1043937A1 (es) |
MX (1) | MX9602689A (es) |
WO (1) | WO1995019784A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5198541A (en) * | 1987-08-11 | 1993-03-30 | New York University | Dna encoding bactericidal/permeability-increasing proteins |
US5652332A (en) * | 1993-03-12 | 1997-07-29 | Xoma | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
US6686332B1 (en) * | 1993-10-15 | 2004-02-03 | Xoma Corporation | Method of treating depressed reticuloendothelial system function |
US5643875A (en) * | 1994-01-24 | 1997-07-01 | Friedmann; Nadav | Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products |
US5447913A (en) * | 1994-03-11 | 1995-09-05 | Xoma Corporation | Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
US5494896A (en) * | 1995-03-31 | 1996-02-27 | Xoma Corporation | Method of treating conditions associated with burn injuries |
CA2227292A1 (en) * | 1995-07-20 | 1997-02-06 | Xoma Corporation | Anti-fungal peptides |
US5741779A (en) * | 1996-05-10 | 1998-04-21 | Xoma Corporation | Antithrombotic materials and methods |
PT914144E (pt) * | 1996-05-10 | 2001-05-31 | Univ Texas | Utilizacoes terapeuticas de produtos de proteinas bip contra a meningococcemia humana |
DE69719754D1 (de) * | 1996-05-23 | 2003-04-17 | Xoma Technology Ltd | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung |
US5888973A (en) * | 1996-08-09 | 1999-03-30 | Xoma Corporation | Anti-chlamydial uses of BPI protein products |
US6482796B2 (en) * | 1996-11-01 | 2002-11-19 | Xoma Corporation | Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients |
US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
US6013631A (en) | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
CA2347250A1 (en) | 1998-10-22 | 2000-04-27 | Sau-Chi Betty Yan | Methods for treating sepsis |
ATE239492T1 (de) * | 1999-01-22 | 2003-05-15 | Xoma Technology Ltd | Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen |
ES2257446T3 (es) * | 2000-10-17 | 2006-08-01 | Besst-Test Aps | Ensayo para detectar directamente un indicador de inflamacion en una muestra de fluido corporal. |
CA2430588A1 (en) * | 2000-12-01 | 2002-07-18 | Xoma Technology Ltd. | Modulation of pericyte proliferation using bpi protein products or bpi inhibitors |
US20060264353A1 (en) * | 2002-03-21 | 2006-11-23 | Maxey Kirk M | Prostaglandin f2alpha analogs and their use in combination with antimicrobial proteins for the treatment of glaucoma and intraocular hypertension |
US20080306768A1 (en) * | 2005-03-21 | 2008-12-11 | Medem, Inc. | Healthcare Notification Method And System Including A Healthcare Website |
AU2010210537B2 (en) * | 2009-02-06 | 2015-06-18 | Astute Medical, Inc. | Diagnosis and prognosis of renal injury and renal failure |
GB201319621D0 (en) | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Antimicrobial agents and their use in therapy |
GB201319620D0 (en) | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Immunosuppressive agents and their use in therapy |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5198541A (en) * | 1987-08-11 | 1993-03-30 | New York University | Dna encoding bactericidal/permeability-increasing proteins |
EP0375724B1 (en) * | 1987-08-11 | 1995-05-31 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
US5171739A (en) * | 1989-02-14 | 1992-12-15 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and preventation thereof using a BPI protein |
US5308834A (en) * | 1989-02-14 | 1994-05-03 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and prevention thereof using a BPI protein |
US5334584A (en) * | 1989-02-14 | 1994-08-02 | Incyte Pharamaceuticals, Inc. | Recombinant, non-glycosylated bpi protein and uses thereof |
US5089274A (en) * | 1989-02-14 | 1992-02-18 | Incyte Pharmaceuticals, Inc. | Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders |
US5234912A (en) * | 1989-02-14 | 1993-08-10 | Incyte Pharmaceuticals, Inc. | Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof |
DE69128968T2 (de) * | 1990-12-03 | 1998-10-08 | Univ New York | Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke |
US5348942A (en) * | 1993-03-12 | 1994-09-20 | Xoma Corporation | Therapeutic uses of bactericidal/permeability increasing protein products |
ATE269099T1 (de) * | 1993-10-15 | 2004-07-15 | Xoma Technology Ltd | Bpi-protein-produkte für definierte funktionen des reticuloendothelialen systems |
US5643875A (en) * | 1994-01-24 | 1997-07-01 | Friedmann; Nadav | Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products |
-
1994
- 1994-08-16 US US08/291,112 patent/US5643875A/en not_active Expired - Fee Related
-
1995
- 1995-01-24 CN CN95191325A patent/CN1145033A/zh active Pending
- 1995-01-24 JP JP7519768A patent/JPH09508130A/ja not_active Withdrawn
- 1995-01-24 AU AU16944/95A patent/AU703728B2/en not_active Ceased
- 1995-01-24 WO PCT/US1995/001151 patent/WO1995019784A1/en not_active Application Discontinuation
- 1995-01-24 EP EP01121005A patent/EP1161952A3/en not_active Withdrawn
- 1995-01-24 EP EP95908723A patent/EP0741575A1/en not_active Ceased
- 1995-01-24 US US08/378,228 patent/US5753620A/en not_active Expired - Fee Related
- 1995-01-24 CA CA002181816A patent/CA2181816A1/en not_active Abandoned
- 1995-01-24 MX MX9602689A patent/MX9602689A/es not_active Application Discontinuation
-
1998
- 1998-05-18 US US09/081,166 patent/US5952302A/en not_active Expired - Fee Related
-
1999
- 1999-09-02 US US09/388,758 patent/US6191112B1/en not_active Expired - Lifetime
-
2000
- 2000-12-08 US US09/733,613 patent/US6586400B2/en not_active Expired - Fee Related
-
2002
- 2002-06-04 HK HK02104223.9A patent/HK1043937A1/zh unknown
-
2006
- 2006-08-28 JP JP2006231410A patent/JP2006321818A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US5643875A (en) | 1997-07-01 |
AU703728B2 (en) | 1999-04-01 |
CA2181816A1 (en) | 1995-07-27 |
HK1043937A1 (zh) | 2002-10-04 |
EP0741575A1 (en) | 1996-11-13 |
WO1995019784A1 (en) | 1995-07-27 |
US6586400B2 (en) | 2003-07-01 |
EP1161952A2 (en) | 2001-12-12 |
AU1694495A (en) | 1995-08-08 |
EP1161952A3 (en) | 2002-01-02 |
US6191112B1 (en) | 2001-02-20 |
JPH09508130A (ja) | 1997-08-19 |
CN1145033A (zh) | 1997-03-12 |
US5753620A (en) | 1998-05-19 |
JP2006321818A (ja) | 2006-11-30 |
US5952302A (en) | 1999-09-14 |
US20020094952A1 (en) | 2002-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9602689A (es) | Usos terapeuticos humanos de los productos de proteina bpi. | |
Ramasastry | Acute wounds | |
Garraud et al. | Wound healing: time to look for intelligent,‘natural’immunological approaches? | |
Lacci et al. | Platelet-rich plasma: support for its use in wound healing | |
Moldawer et al. | Circulating interleukin 1 and tumor necrosis factor during inflammation | |
ATE292979T1 (de) | Verwendung von aktiviertem protein-c zur behandlung überschiessender blutgerinnung bei sepsis | |
DE60140794D1 (de) | Von casein abgeleitete peptide und deren anwendung für die therapie | |
DE69030880D1 (de) | Zusammensetzung zur Stimulierung des Immunsystems | |
CA2185155A1 (en) | Therapeutic uses of bactericidal/permeability-increasing protein dimer products | |
DE69719754D1 (de) | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung | |
ATE77751T1 (de) | Mittel zur behandlung von knochenkrankheiten. | |
Cancela et al. | Use of platelet-rich plasma (PRP) in treating chronic wounds | |
Galvan | Effects of heparin on wound healing | |
Elsayed et al. | Evaluation of the effect of platelet-rich plasma on post-burn scars | |
WO1996020950A3 (en) | Compositions and methods for treating rheumatoid arthritis | |
NZ335401A (en) | Therapeutic uses of BPI protein products in cystic fibrosis patients | |
Kikyo et al. | Purification of a cell growth factor from a human lung cancer cell line: its relationship with ferritin | |
Susilo et al. | Effects of hyperbaric oxygen therapy on the increase of iNOS and NFKB expressions and the acceleration of wound healing process during inflammation and proliferation phases | |
Abramson | Iron deficency anemia: What's the cause? | |
Virgolino | Tips and Tricks for Healing Potential in Different Tissue | |
Heathfield et al. | Chlorothiazide in Treatment of Carpaltunnel Syndrome | |
Deconinck et al. | Inhibition of ADAMTS13 prevents the loss of high molecular weight von Willebrand factor multimers in an in vitro left ventricular assist device | |
Riahy et al. | Physiology of Cutaneous Wound Healing: A Narrative Review Article | |
Arisawa et al. | Deleted form of hepatocyte growth factor ameliorates the mortality rate of severe thermal injury in rats | |
Lever et al. | The proteins in Pemphigus Vulgaris: III. The effect of infusions of human serum albumin on the proteins in the blood serum of patients with Pemphigus Vulgaris |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |